Science Corporation has secured European Union approval for its PRIMA retinal implant, a device designed to restore vision in people with certain forms of blindness. The green light from EU regulators marks a significant step for the company, which now aims to hit $100 million in annual revenue to prove the technology's commercial viability.
How the PRIMA implant works
The PRIMA system is a tiny chip implanted under the retina. It converts light into electrical signals that stimulate remaining retinal cells, effectively bypassing damaged photoreceptors. The technology targets patients with geographic atrophy, a severe form of age-related macular degeneration that leads to central vision loss. Unlike earlier retinal prostheses that required bulky external equipment, PRIMA is wireless and powered by a pair of glasses that project near-infrared light onto the chip.
Clinical trials have shown that some patients can read letters, recognize faces, and navigate low-light environments after receiving the implant. The company has not released full trial data publicly, but the EU approval suggests regulators were satisfied with the safety and efficacy evidence.
Why EU approval matters
The European Medicines Agency's decision opens a market of roughly 500 million people across the EU. For Science Corporation, this is the first major regulatory clearance for its lead product. The company is a privately held neurotech firm based in California. It has raised venture capital but has not disclosed its valuation. The PRIMA implant is its most advanced candidate, and the EU approval gives it a foothold in a region with aging populations and high demand for vision-restoring therapies.
Competitors in the retinal implant space include Second Sight Medical Products, which has faced financial struggles, and Pixium Vision, which is developing a similar system. Science Corporation's approach uses a higher-density electrode array, which may offer better resolution.
The $100 million revenue target
Company leadership has stated that reaching $100 million in annual revenue is the key benchmark to demonstrate the product's viability. That figure would cover development costs and signal to investors that the technology can sustain itself commercially. The price of the PRIMA implant has not been disclosed, but similar devices can cost tens of thousands of dollars per patient, including surgery and rehabilitation.
To hit that target, Science Corporation will need to secure reimbursement agreements with national health systems and private insurers across Europe. The company also plans to seek approval in other regions, including the United States, where the FDA has not yet ruled on the device.
The neurotech market is growing, but retinal implants remain a niche. Only a few thousand patients worldwide have received such devices. Science Corporation's success will depend on how quickly it can scale manufacturing, train surgeons, and convince payers that the implant is worth the cost.
For now, the company is focused on the European launch. It has not announced a timeline for when the first patients will receive the implant commercially. The approval is a milestone, but the real test begins now: turning regulatory clearance into a sustainable business.
